Overview
Biocon Biologics Limited is a unique, fully integrated global biosimilars player, making a difference to over 5.8 million lives every year, in more than 120 countries.
With established capabilities in the development, manufacturing and commercialization of high-quality biosimilars, we enable equitable access to cost-effective, lifesaving biosimilars for patients worldwide. Our 45+ year legacy of being on the cutting edge of science has helped us simultaneously build global scale with a competitive cost structure to transform healthcare, and transform lives.
Biocon Biologics offers a comprehensive portfolio of 20 biosimilars — one of the widest and deepest in the industry. Having completed the acquisition of Viatris’ global biosimilar business, we are leveraging end-to-end capabilities from lab to market, to widen our reach and push us to greater heights in the biosimilars business.
Biocon Biologics is a subsidiary of the publicly listed Biocon Limited. Please refer to the Biocon Limited Investor Section for statutory information.
Recent Equity Investments
The Investor Relations section contains information about Biocon Biologics' business for stockholders, potential investors, and financial analysts.
